>Congratulations to ACROBiosystems being Listed on domestic Shenzhen Stock Exchange
ACROBiosystems is pleased to announce that on October 18, 2021 Beijing local time, the company was listed on the Shenzhen Stock Exchange.
Exploring the forefront of global biotechnology, ACROBiosystems has developed a number of core technologies and obtained patent authorizations. The company currently serves more than 5,000 global customers and has established long-term stable relationship with World Top 20 pharmaceutical companies. Aside from ACROBiosystems, the company also created other brands such as bioSeedin, ACRODiagnostics, and etc. which have established significant brand influence globally.
ACROBiosystems' catalog includes a comprehensive list of disease-associated biomarkers and drug targets from human and other common species. ACROBiosystems has passed ISO 9001 and ISO 13485 certification. Under this strict quality control system, the company is proud to be recognized by customers for high quality products and batch-to-batch consistency.
ACROBiosystems’s vision is to become a global cornerstone enterprise and serve as a platform for the biopharma and healthcare industry. The company grows from bringing values to customers to creating values for the global pharmaceutical industry. ACROBiosystems is dedicated to accelerating the process of therapeutic drug development to its better clinical application and ultimately human health through rapid and continuous technology development and product iteration.
ACROBiosystems has been and always will be open for cooperation. Join the company in drug discovery and development, translational and clinical practice, as well as the development and commercialization of innovative molecular profiling and diagnostic technologies.
Together, make a difference.
This web search service is supported by Google Inc.